2018
DOI: 10.2217/bmm-2018-0155
|View full text |Cite
|
Sign up to set email alerts
|

Plasma Heat Shock Protein 90-Alpha Have an Advantage in Diagnosis of Colorectal Cancer at Early Stage

Abstract: HSP90 is a potential biomarker for the diagnosis of early CRC.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
23
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 29 publications
(24 citation statements)
references
References 20 publications
1
23
0
Order By: Relevance
“…Moreover, the relationship between these biomarkers and clinical features is also controversial (Dolscheid-Pommerich et al, 2017; Wild et al, 2010), which reduced their diagnostic and prognostic value in CRC. In recent years, a growing number of independent indicators in CRC have been explored, such as serum pentraxin-3 (Liu, Zhao & Guo, 2018), CNPY2 (Peng et al, 2018), and HSP-90 α (Kasanga et al, 2018), which have been of great help in the diagnosis and prognosis of CRC; however, the reliability of these biomarkers requires further study.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, the relationship between these biomarkers and clinical features is also controversial (Dolscheid-Pommerich et al, 2017; Wild et al, 2010), which reduced their diagnostic and prognostic value in CRC. In recent years, a growing number of independent indicators in CRC have been explored, such as serum pentraxin-3 (Liu, Zhao & Guo, 2018), CNPY2 (Peng et al, 2018), and HSP-90 α (Kasanga et al, 2018), which have been of great help in the diagnosis and prognosis of CRC; however, the reliability of these biomarkers requires further study.…”
Section: Introductionmentioning
confidence: 99%
“…Similar studies have been performed on colorectal cancer (CRC). For example, HSP90 in plasma confers an advantage in the diagnosis of early CRC [9]. However, whether HSP90 can be used as a biomarker for the evaluation of therapeutic effects is unknown.…”
Section: Ivyspringmentioning
confidence: 99%
“…In 2009, Wang et al found patients with liver cancer had higher level of HSP90α in plasma, and the expression level correlated with the stage of liver cancer, which suggested HSP90α can be used as a tumor marker for early screening [6]. Previous studies of HSP90α mainly involved in liver cancer and colorectal cancer et al [7][8][9][10][11], while studies on the expression level of HSP90α on patients with lung cancer were really rare, and the correlations between HSP90α and other tumor biomarkers were not well described.…”
Section: Introductionmentioning
confidence: 99%